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Abstract
Background: TAR DNA binding protein, encoded by TARDBP, was shown to be a central component of ubiquitin-positive,
tau-negative inclusions in frontotemporal lobar degeneration (FTLD-U) and amyotrophic lateral sclerosis (ALS). Recently,
mutations in TARDBP have been linked to familial and sporadic ALS.
Methodology/Principal Findings: To further examine the frequency of mutations in TARDBP in sporadic ALS, 279 ALS cases
and 806 neurologically normal control individuals of European descent were screened for sequence variants, copy number
variants, genetic and haplotype association with disease. An additional 173 African samples from the Human Gene Diversity
Panel were sequenced as this population had the highest likelihood of finding changes. No mutations were found in the
ALS cases. Several genetic variants were identified in controls, which were considered as non-pathogenic changes.
Furthermore, pathogenic structural variants were not observed in the cases and there was no genetic or haplotype
association with disease status across the TARDBP locus.
Conclusions: Our data indicate that genetic variation in TARDBP is not a common cause of sporadic ALS in North American.
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Introduction
Amyotrophic lateral sclerosis (ALS, OMIM #105400) is a rare
and devastating neurodegenerative disorder of unknown etiology
characterized by rapidly progressive paralysis leading to death due
to respiratory failure, typically within 3–5 years of symptom onset.
Population-based epidemiological studies of the disease show that
between 1.6% and 5.7% of cases are familial in nature, whereas
the remaining 95% occur sporadically throughout the population
[1],[2]. Various genes that cause familial ALS have been
identified, including copper/zinc superoxide dismutase [3],
dynactin 1 [4][5], alsin [6], senataxin [7], and vesicle-associated
protein B [8]. In contrast to familial ALS, the genetics of the
sporadic form are poorly understood and it is not known if
sporadic ALS is monogenic (i.e., a single-gene disorder), polygenic
(i.e., multiple interacting genes), multi-factorial (i.e., interacting
genetic and environmental factors), or arises from some unknown
non-genetic cause [9].
The neuropathology of ALS is characterized by the abnormal
accumulation of insoluble ubiquitin proteins in the cytoplasm of
degenerating motor neurons [10]. Recently, TAR DNA-binding
protein 43 (TARDBP, OMIM #605078) was recognized as a
major constituent of these neuronal cytoplasmic inclusions
[11],[12],[13]. TDP-43 protein is evolutionary conserved and its
structure consists of a glycine-rich domain and two RNA
recognition motifs [14]. The exact function of TDP-43 remains
unclear, though it is known to bind DNA and RNA (such as
human immunodeficiency virus type 1 TAR DNA sequence
motifs) [15], and to be involved in the regulation of messenger
RNA splicing and exon skipping [16]. Four studies have
independently reported TARDBP mutations in familial forms of
ALS displaying autosomal dominant inheritance and in sporadic
ALS. An A315T mutation in exon 6 of TARDBP was reported to
segregate with disease within a multi-generational ALS family and
this sequence variant was not found in 1,505 control subjects [17].
In other study, a missense mutation M337V in exon 6 of TARDBP
segregated with disease within an ALS family across two
generations. In addition, two missense mutations (Q331K and
G294A) were identified in two of 372 sporadic ALS cases screened
for mutations (representing 0.5% of the total cohort). None of the
three mutations were identified in 1,262 control subjects [18]. In a
separate study of 200 individuals with ALS from France and
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TARDBP including the previously identified A315T missense
mutation and A382T in small families and D169G, G287S,
G348C, R361S, N390D and N390S in individual sporadic cases
[19]. In the latest study, two additional missense mutations
(G290A and G298S) were identified in familial ALS cases [20].
None of the sequence variants identified in sporadic ALS patients
have been seen in more than one case.
In this study, we undertook mutational screening of TARDBP in
a cohort of 279 North American sporadic ALS cases and in a
cohort of 806 ethnically-matched controls. The same case-control
cohort had been previously genotyped using Illumina Human-
Hap550 BeadChips which assay over 550,000 tagged SNPs across
the human genome [9]. This genotype data was analyzed to
identify (a) genomic structural variants of the TARDBP locus
relevant to the pathogenesis of sporadic ALS, (b) genetic
association of SNPs within TARDBP with disease status, and (c)
common haplotypes across the TARDBP locus that alter risk of
motor neuron degeneration. Finally, we sequenced TARDDP in
the African samples of the Human Gene Diversity Panel (n=173)
to examine genetic diversity of this gene in non-Caucasian
populations.
Materials and Methods
ALS and control series
The case cohort used in this study consisted of 279 white, non-
Hispanic subjects diagnosed with probable or definite sporadic
ALS [21]. Of these, 181 were men and 98 were women and the
average age of symptom onset was 55 years (range, 19–82 years).
58 patients described bulbar-onset disease, 217 patients presented
with spinal-onset disease, 2 patients had generalized symptoms at
onset and the remaining 2 patients presented with respiratory
symptoms. These samples are publicly available from the NINDS
Neurogenetics Repository at the Coriell Institute for Medical
Research, NJ, USA (www.coriell.org).
The control cohort comprised of 806 neurologically normal
white, non-Hispanic individuals obtained from the same NINDS
Neurogenetics repository. These samples are available as pre-
compiled panels (NDPT002, NDPT006, NDPT009, NDPT019 to
NDPT024). None of the control samples had a medical history of
ALS, Alzheimer’s disease, ataxia, autism, bipolar disorder, brain
aneurysm, dementia, dystonia, or Parkinson’s disease and none
had any first-degree relative with a known primary neurological
disorder. The control and case cohorts were drawn from the same
ethnic origin (i.e. Caucasian) at different clinical sites throughout
the United States, but the control samples were not matched by
age or sex with the ALS samples [9]. The control cohort consisted
of 335 men and 471 women and the mean age at sample collection
was 59 years (range 15–95 years).
An additional series of 173 anonymous African samples that are
part of the Human Gene Diversity Panel (HGDP) [22] were
included in the mutational analysis as controls to evaluate the
genetic variability of TARDBP in non-Caucasian populations.
These samples originated from eight different African populations,
namely Biaka Pygmy (n=35), Mozabite (n=26), Bedouin (n=25),
Mandenka (n=24), Yoruba (n=23), Bantu (n=20), Mbuti Pygmy
(n=13) and San (n=7). All patients and controls gave written
informed consent to participate in the study.
DNA Sequencing
All the coding exons and 30bp of the flanking intron-exon
boundaries of TARDBP (NM007375.3) were PCR amplified using
primers designed using Primer3 software (available upon request)
and Roche FastStart PCR MasterMix polymerase (Roche
Diagnostics Corp., IN). Each PCR product was sequenced using
Applied Biosystems BigDye terminator v3.1 sequencing chemistry
and run on an ABI3730xl (Applied Biosystems, CA) genetic
analyzer as per manufacturer’s instructions. The sequences were
analyzed with Sequencher software, version 4.2 (Genecodes, VA).
SNP chip genotyping
All 279 US ALS samples included in this study had been
previously genotyped with Illumina Infinium II HumanHap550
SNP chips (Illumina, San Diego, CA, USA) as part of a whole
genome association study of sporadic ALS [9]. DNA from 594
control subjects had also been genotyped using HumanHap550
SNP chips. The remaining 212 control individuals were assayed
with both Illumina Infinium II HumanHap240S SNP chips [9]
and HumanHap317 SNP chip [23] and the data from both these
chips were combined to provide a final control genotyping dataset
containing the same 555,000 SNPs as the cases. Raw genotype
data for 258 of the ALS cases and 259 of the control samples have
previously been made publicly available [9,23].
All samples were genotyped at the Laboratory of Neurogenetics,
National Institute on Aging, Bethesda, MD according to the
manufacturer’s protocol. The resulting genotypes were visualized
using the BeadStudio software package version 3.1.4 (Illumina,
Inc.) using Human Genome Build 17 as reference. Any sample
with a call rate below 95% were repeated on a fresh DNA aliquot
and if the call rate persisted below this level the sample was
excluded from the analysis.
Copy number variant analysis
Two metrics generated during SNP chip genotyping (namely,
logR ratio which is a normalized value representing the total
amount of DNA hybridized to a SNP probe, and B allele
frequency which represents the fraction of intensity due to the B
allele) were manually inspected to determine the number of allele
copies at each SNP. Using this data, the TARDBP locus (plus the
flanking 100kb) was evaluated for structural genomic variants. A
two-tailed Fisher exact test (1 degree of freedom) was then used to
evaluate the significance of differences between cases and controls
at each SNP. Duplications and deletions were analyzed separately.
The Database of Genomic Variants (http://projects.tcag.ca/
variation/, accessed 28
th January 2008) was reviewed to determine
if identified CNV had been previously described.
Genetic and haplotype association analysis
42 SNPs within the TARDBP locus and the flanking 100kb were
genotyped by the Illumina HumanHap550 BeadChip and were
available for analysis. SNP and haplotype association were
computed for each SNP using the PLINK toolset [24]. Each
SNP was required to have a call rate greater than or equal to 95%
and each SNP was tested for departures from Hardy-Weinberg
equilibrium. Association tests were computed using an additive
model (Cochran-Armitage trend test, 1 degree of freedom), and
using the three-marker sliding-window haplotype-association
algorithm contained within PLINK. Odds ratios with upper and
lower bound 95% confidence intervals were computed for the
minor allele of each SNP.
Results
Table 1 details the sequence variants found in the 279 ALS
cases, the 806 North American controls and in the 173 African
samples that were screened as part of this study. Pathogenic
mutations were not identified in any of the 279 ALS cases. Five of
TDP-43 and Sporadic ALS
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ND10379) carried the synonymous variation p.A66A (c.198 T.C)
in exon 2 of TARDBP, but this sequence variant was likely to be a
benign polymorphism as it was found in eight of the Caucasian
controls and in a single Bedouin sample of the HGDP.
Furthermore, the previously reported pathogenic sequence
variants were not present in any of the case or control samples,
though a synonymous variant involving codon 315 (p.A315A,
c.945G.A) was identified in a single Caucasian control individual
(ND05681).
Nineteen control samples were excluded due to poor quality
genotyping on the Illumina HumanHap SNP chips (i.e. call rates
,95%). Thus the final cohort for which genotyping chip data was
available consisted of 279 ALS cases and 787 control individuals.
Copy number analysis of the TARDBP locus using data generated
with Illumina Infinium II HumanHap550 BeadChips did not
reveal structural abnormalities affecting the TARDBP gene
(675kb) in any of the 279 cases.
Statistical analysis of association was done for 42 tagging SNPs
within the TARDBP gene and the flanking 100kb, irrespective of
Hardy-Weinberg disequilibrium or minor allele frequency. One
SNP (rs12059717 located 17.kb from the gene) was excluded due
to low call rate. None of the remaining 41 SNPs were significantly
associated with altered risk of developing ALS under the additive
model. Similarly, no haplotype significantly altering disease risk
was identified (Supplementary Tables S1 and S2).
Discussion
In this study we evaluated the role of TARDBP in the
pathogenesis of sporadic ALS by undertaking sequence mutational
analysis, as well as evaluating genomic structural variation, genetic
association and haplotype association in a cohort of 279 North
American ALS patients and 806 neurologically normal controls.
We did not find any genetic or genomic evidence that TARDBP
was associated with sporadic disease. Although the size of our
cohort is not large enough to exclude this gene as the underlying
etiology of occasional rare cases of sporadic ALS, our data
indicates that mutations in TARDBP are not a common cause of
sporadic motor neuron degeneration in the North American
population (i.e. no greater than 0.4% of all cases). Although
mutations in the TARDBP gene are rare, the protein may still play
an important role in ALS. In fact, several studies have linked ALS
pathogenesis to perturbations of TDP-43 nuclear trafficking,
solubility and intracellular accumulation [25–27].
Our data agree with previous reports of a negative association
between TARDP and ALS in 237 sporadic patients [28].
Furthermore, we did not find any case or control samples in our
series that carried any of the previously reported pathogenic
mutations (A315T, A382T or M337V) that have been reported in
familial cases, or any of the 8 variants (D169G, G287S, G294A,
Q331K, G348C, R361S, N390D and N390S) that each have been
reported in single sporadic cases. Although the published
segregation data strongly supports the pathogenicity of the
M337V and A315T mutations within these families, the lack of
further examples of the eight mutations identified within sporadic
ALS cases suggests that the true pathogenic nature of these
variants remains to be established. Interestingly, all the variants
found and considered by the authors as pathogenic, with the
exception of D169G in exon 4, are situated in exon 6; all non-
synonymous but benign variants identified by us, lie outside of this
exon. These mutations may alter the normal function/transport of
TDP-43 or they may cause a toxic gain of function of the protein
by altering its C-terminal [19].
Structural variants of the TARDBP gene were not a cause of
sporadic ALS in our dataset. Although the density of SNPs on the
Illumina HumanHap550 is not sufficient to exclude small deletions
orinsertions (42SNPsover212.9Kb,1 SNPper5Kb), our sequence
analysis did excluded the presence of small deletions/insertions
within the coding sequence and flanking introns of TARDBP.
Finally, neither genetic association nor haplotype association with
disease was observed across the TARDBP locus. Although this
analysis was based on a relatively small number of markers, these 42
SNPs were tagging SNPs that are representative of neighboring
sequence variation and extract a larger amount of genetic
information than a similar number of randomly chosen SNPs.
We sequenced TARDBP in a cohort of 173 African samples to
determine the variability of the gene in a non-Caucasian
population and because this population carried the highest
likelihood of finding changes. As expected, given the greater
genetic variation known to exist within African populations, SNPs
were more commonly present in this cohort compared to the
Caucasian controls (6,9% compared to 1,1%). This observation is
consistent with the older age of these populations with the
consequent accumulation of sequence variants over a greater
number of generations [29,30]. Interestingly, we observed only
two non-synonymous SNPs within TARDBP in both the African
and Caucasian controls (i.e. D65E and A90V). We speculate that
the biological importance of this gene has resulted in negative
selective pressure against variants that alter TDP-43 amino-acid
sequence.
In conclusion, our comprehensive genetic and genomic
assessment of TARDBP failed to identify disease associated variants
in the North American patients studied here. Taken together with
previous reports, we conclude that mutations in TARDBP are not a
common cause of sporadic motor neuron degeneration.
Supporting Information
Table S1 Statistical analysis of association of the 41 tagging
SNPs within the TARDBP gene and flanking 100kb and the risk of
disease. None of the 41 tagging SNPs was significantly associated
with an altered risk of developing ALS. CHR: Chromosome; bp
position: base pairs position relative to human genome build 36;
p,0.05 values were considered statistically significant.
Found at: doi:10.1371/journal.pone.0002450.s001 (0.10 MB
DOC)
Table S2 Statistical analysis of association of haplotypes within
the TARDBP locus and the risk of disease. None of the haplotypes
Table 1. Sequence variations found in the TARDBP gene in
the 279 ALS cases, 806 North American controls and 173
African samples.
Exon Variant
Number of
ALS cases
Number of
controls Origin of samples
2 p. A66A 5 8 1 African (Bedouin) 12
Caucasian
2 p. D65E 0 1 African (Yoruba)
3 p. A90V 0 2 Caucasian
5 p. P225P 0 4 African (1 Biaka Pygmies; 2
Mandenka; 1 Yoruba)
6 p. N352N 0 5 African (4 San; 1 Bantu)
doi:10.1371/journal.pone.0002450.t001
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p,0.05 values were considered statistically significant.
Found at: doi:10.1371/journal.pone.0002450.s002 (0.24 MB
DOC)
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